Cleerly ISCHEMIA vs cmAngio®
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease and the likelihood of ischemia at a vessel level. This tool is ideal for physicians utilizing CCTA scans to precisely characterize coronary plaque, assess stenosis severity, and guide personalized treatment plans for patients with suspected or known heart disease.
View Cleerly ISCHEMIA →Choose cmAngio® if…
Choose cmAngio® if you aim to leverage existing mammography data for early cardiovascular risk assessment in women. This AI software is best suited for identifying Breast Arterial Calcifications (BAC) on both FFDM and DBT exams, providing valuable insights into a patient's cardiovascular health without requiring additional radiation or procedures.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | cmAngio® |
|---|---|---|
| Pricing | Unknown | Paid, out-of-pocket |
| Deployment | Web-based solution | Cloud-based, integrates with any DICOM-compliant viewer |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA offers comprehensive interactive web-based reports and explicitly mentions compliance with usability engineering standards, including formative and summative evaluations with cardiac specialists. While cmAngio boasts quick installation and compatibility with any DICOM viewer, Cleerly's focus on interactive reporting and validated usability suggests a potentially richer user experience.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides direct diagnostic and prognostic value for coronary artery disease by non-invasively determining the likelihood of ischemia at a vessel level, estimating FFR, and characterizing plaque, validated in multiple trials against invasive FFR. cmAngio offers valuable cardiovascular risk assessment by detecting breast arterial calcifications on mammograms, but Cleerly's immediate diagnostic and prognostic impact on active heart disease management is more direct and comprehensive.
Pricing & Value
Cleerly ISCHEMIACleerly ISCHEMIA has a significant advantage with established Category I CPT codes (75580 for FFR estimation and 75577 for plaque analysis in 2026), providing clear reimbursement pathways and reducing financial uncertainty for providers. While both tools require contacting for specific pricing, Cleerly's transparent reimbursement structure offers a stronger value proposition for healthcare systems.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA explicitly states it has a Business Associate Agreement (BAA) and is HIPAA compliant, which is a critical component for enterprise-level data handling and compliance in healthcare. Although cmAngio is also HIPAA compliant and has expanded compatibility with imaging platforms, its requirement to contact the vendor for BAA details introduces a minor hurdle compared to Cleerly's upfront declaration of BAA availability.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates higher innovation by non-invasively estimating fractional flow reserve (FFR) and providing a comprehensive 3-in-1 assessment of atherosclerosis, stenosis, and ischemia from a single CCTA, which previously required more invasive or separate functional tests. While cmAngio innovatively repurposes existing mammography data for cardiovascular risk assessment, Cleerly's advancement in functional cardiac assessment from non-invasive imaging represents a more profound technological leap in its field.
Support & Docs
Cleerly ISCHEMIACleerly ISCHEMIA provides a more extensive and clearly categorized array of support and documentation resources, including patient education, FAQs, billing guidelines, imaging protocols, and various publications. While cmAngio mentions an Operator's Manual and publications, Cleerly's broader range of accessible materials for different stakeholders suggests a more comprehensive support ecosystem.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | cmAngio® |
|---|---|---|
| Name | Cleerly ISCHEMIA | cmAngiou00ae |
| Primary Use Case / Target Condition | Non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. |
| Key Analysis Method | AI-enabled CCTA analysis; Non-invasive fractional flow reserve (FFR) estimation; Coronary plaque characterization; Stenosis severity assessment. | AI-based detection of Breast Arterial Calcifications (BAC). |
| Input Data Type | CCTA scans | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams |
| Specialties | Cardiology, Radiology | Cardiology, Obstetrics & Gynecology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and cmAngio®.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or cmAngio®
Backers
Who funded each tool's parent company.